[Effectiveness of aromatase inhibitors in comparison with metformin for neoadjuvant treatment in patients with endometrial cancer].

We compared the efficacy of endometrial cancer neoadjuvant treatment in 38 patients receiving nonsteroid (letrozol, anastrozol) or steroid (ekzemestan) aromatase inhibitors and 12 patients receiving metformin. The changes in glucose metabolism were revealed in 26.3% of patients treated with aromatase inhibitors and 16.

[Criteria for evaluating the effectiveness of aromatase inhibitors in the neoadjuvant treatment of patients with endometrial carcinoma].

Clinical and experimental effects of neoadjuvant treatment of endometrial cancer patients with non-steroidal aromatase inhibitors: letrozole (femara, n=10, 2.5 mg/day, 14 days), anastrozole (arimidex, n=15,1 mg/day, 28 days) and exemestane (aromazine, n=13, 25 mg/day, 14 days) were compared. Administration of anastrozole was mostly frequently followed by pain relief in the lower abdomen and/or decreased rates of uterine discharge.

[Features of ultrasound diagnosis of non-epithelial ovarian carcinoma].

Ultrasound examination using color Doppler imaging was used in 70 patients with non-epithelial ovarian carcinoma and 23 patients with subserous nodes of uterine myoma. Diagnosis was confirmed by histological assay of resected material. The procedure can be used for differentiated diagnosis between non-epithelial ovarian carcinoma and subserous nodes of uterine myoma, as well as for appraisal of individual features of tumor so that adequate treatment might be selected.

[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma].

The clinical and endocrine-related effects of 2-week preoperative treatment of endometrial carcinoma patients with a non-steroid inhibitor of letrozole aromatase (femara 2.5 mg/day, n=10) and a steroid inactivator of the enzyme (exemestane 25 mg/day, n=13) were compared. In the first group, pain relief in the lower part of the belly and/or decreased uterine discharge were reported in two cases, as well as a 31% drop in the mean endometrial M-echo (ultrasound) signal.

[Risk of endometrial hyperplasia and carcinoma in breast cancer patients receiving adjuvant tamoxifen].

The antiestrogen drug tamoxifen, which is widely used in adjuvant hormone therapy of breast cancer, presents certain risk of causing hyperplasia and endometrial carcinoma. Our clinical data on 1,969 breast cancer patients (stage I-III) (tamoxifen--947; control--1,022) showed a double rise in endometrial carcinoma risk in cases receiving hormone therapy. Endometrial carcinoma incidence in tamoxifen-treated patients was 3% while in the untreated ones--1.

Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects.

Objective: To investigate the short-term hormonal and clinical effects of the aromatase inhibitor letrozole (Femara) in patients with endometrial cancer.

Materials And Methods: Ten previously untreated, post-menopausal patients (mean age 59 years) with endometrial cancer, predominantly stage I disease, received letrozole 2.5mg per day for 14 days before surgery.

[Doppler investigation of blood flow in uterine vessels of patients with endometrial cancer].

125 suspects for endometrial pathology were examined to evaluate clinical significance of color Doppler sonography for comprehensive diagnosis of endometrial carcinoma. This pathology was identified in 114; atypical hyperplasia--11. The data on combined application of traditional ultrasound and color Doppler sonography were compared with those on clinical and postoperative histological examinations.

[Neoadjuvant use of the aromatase inhibitor letrozole in uterine cancer: endocrine and clinical effects].

Endometrial cancer (EC) is estrogen-dependent tumor in the hormonal treatment of which mostly progestins are used. During last 5-7 years feasibility of aromatase inhibitors use in EC is discussed without any special practical move in this direction. To evaluate possible biological response of tumor and patients to such treatment, we conducted a short pilot study involving 10 primary postmenopausal EC patients, mostly stage Ia,b (average age 59) who received letrozole (Femara, Novartis) 2.

[Diagnostic potential of ultrasound examination for tumor recurrence and metastasis].

Ultrasound examination was carried out in 252 patients following specific treatment of uterine and ovarian malignancies. To compare the effectiveness of diagnostic procedures, transabdominal and transvaginal examinations were performed in succession in all the patients using ultrasound (Doppler) technique. Transvaginal study proved relatively more sensitive (98.

[Comparative study of the ploidy and cell proliferation of malignant epithelial neoplasms of various origin (flow cytometric assay)].

Flow cytometry was used for measure DNA content of tumor cells of squamous-cell carcinoma of the tongue and mucosa of the oral cavity fundus, invasive ductal breast carcinoma, endometrial, colonic and rectal adenocarcinomas. Frequency of aneuploidy is characteristic of tumor. Frequency of aneuploidy is high in the oral cavity and breast cancer, colonic and rectal carcinomas and low in cancer of the tongue and endometrium Aneuploidy is associated with nonfavorable clinical and morphological signs of breast cancer, carcinomas of the oral cavity, corpurus uteri and rectum.

[Flow-cytometric study of aneuploidy and proliferative activity of endometrial cancer cells as indicators of tumor aggressiveness].

DNA level and proliferative activity of malignant cells (89), atypical (7), glandular and glandular-cystous hyperplasia (15) of the endometrium and normal endometrium (28) have been assayed by flow cytometry. The results were evaluated versus degree of cell differentiation, depth of invasion and expected clinical prognosis. A reverse relationship was established between aneuplody frequency on the one hand, and cell differentiation degree and poor prognosis, on the other.